Prevalence of markers for hepatitis B virus and vaccination compliance among medical school students in Italy.

The prevalence of markers for hepatitis B virus (HBV) and the rate of compliance with HBV vaccination laws were investigated in a study at Padua University Medical School (Italy). Of 2,361 students, 385 (16.3%) tested negative for antibody to hepatitis B surface antigen. When vaccination was actively offered to these students, there was a low rate of compliance (47.0% [181 students]) but a good rate of seroconversion (93.1% [95 of 102 students]). Screening for HBV markers appears to be crucial to efforts to increase rates of vaccination coverage.

Compliance with hepatitis B virus vaccine: a matter of force?

BACKGROUND: Vaccination for hepatitis B virus has been mandatory in Italy since 1991 for newborns but not for workers exposed to biologic fluids. METHODS: The immunologic status against hepatitis B virus was investigated in 827 paramedical students of Padua University Medical School. The students were subdivided according to sex and 2 age groups: 24 years of age or less and older than 24 years because subjects aged 24 years or less were probably included in the Italian vaccination mandatory period. RESULTS: Subjects born during the mandatory period showed a large compliance to vaccination (94.9%) and without statistically significant difference between males and females compared with the oldest students (67.6%). CONCLUSION: The prevention at work is a matter of public health, not an individual sensitivity. For this reason, the devices to prevent accidents and diseases should be mandatory for all exposed subjects.

Prevalence of childhood exanthematic disease antibodies in paramedical students: need of vaccination.

The immunity to common childhood exanthematic diseases such as varicella, rubella, mumps and measles was evaluated in 1024 students of the degree courses of health professions at Padua University Medical School. Subjects were subdivided according to gender and age (25 years old or less, and older than 25 years). Results showed that the prevalence of positive antibodies (IgG) to varicella and rubella (94.1 and 94.5%, respectively) was significantly higher (p<0.001) than mumps (78.6%) and measles (86.3%). In addition, measles showed a significant higher prevalence than mumps (p<0.001). Prevalence of positive antibodies to rubella in females (97.4%) was significantly higher (p<0.001) than males (87.5%), but only if aged 25 years or less. Furthermore, males older than 25 years were significantly more immune (p<0.001) to measles (93.0%) than younger ones (84.3%). A vaccination strategy was applied but compliance was less than 50%; in addition, about 40.0% of vaccinated subjects eluded control after vaccination. Seroconversion after vaccine appeared high for rubella, mumps and measles (92.3, 88.9 and 88.1%, respectively), but low for varicella (43.8%).

Erythrocyte aminolevulinic acid dehydratase inhibition by cis-platin.

The effect of cis-platin on erythrocyte aminolevulinic acid dehydratase (ALAD) activity was studied in vivo and in vitro. Young male Wistar rats were treated with a single i.p. injection of cis-platin at 2.5, 5.0, and 10.0mg/kg dose. In addition, a single i.p. injection of lead nitrate (1.0mg/kg dose) was administered as positive control. Experiments in vitro were also performed to elucidate the possible mechanism of action. The aminolevulinic acid dehydratase was almost completely inhibited in vitro from 0.5mM concentration, and the IC(50) was stated at 0.265 mM, 20 times higher than lead (IC(50) stated at 0.013 mM). Reduced glutathione, partially but significantly, reactivated in vitro the enzyme treated with cis-platin (0.5 and 5.0mM), whereas zinc showed a positive, significant effect with the higher dose (5.0mM) only. On the contrary, inhibition caused by lead (0.005 mM) was partially, but significantly restored by reduced glutathione, and, almost completely, by zinc. The experiments in vivo show that cis-platin causes a dose- and time-dependent inhibition of ALAD activity with 5.0 and 10.0mg/kg dose, until 66 and 33% of the control activity 96 h after treatment, respectively. The results show that erythrocyte ALAD is sensitive to cis-platin and suggest that the mechanism of enzyme inhibition is a direct interaction with sulfhydryl groups, whereas zinc site appears involved with the higher doses only. This mechanism appears different from lead that prevalently inhibits ALAD removing zinc from the enzyme, other than interacting with sulfhydryl groups.

Synthesis of a palladium(II)-dithiocarbamate complex: biological assay and nephrotoxicity in rats.

A new palladium(II)-dithiocarbamate complex, [Pd(ESDT)Cl](n), was synthesised and its chemical characteristics are discussed. This complex was examined for its cytotoxic properties in human tumour cell lines; for comparison, the cytotoxicity of cisplatin was evaluated under the same experimental conditions. In particular, Pd(II)-complex cytotoxicity on ovarian carcinoma C13 cells, resistant to cisplatin, showed that there seemed to be no cross-resistance between [Pd(ESDT)Cl](n) and cisplatin. The effects on the kidney were also studied. Biochemical investigation on urinary parameters showed that the effects after a single injection are similar to those of cisplatin, with an increase of urinary proteins and enzyme excretion in urine, and a significant decrease of glutamine synthetase activity in the renal tissue. In addition, the Pd(II)-complex caused a significant decrease of p-aminohippuric acid uptake in renal cortical slices relative to cisplatin. On the other hand, histopathological findings showed that the effects of the Pd(II)-complex are more severe and diffuse than the damage caused by cisplatin. Biochemical and histopathological findings show that the Pd(II)-complex affects the pars recta and pars convoluta, in contrast to cisplatin, which only affects the pars recta.